MGX

Business Context and Reporting Period

Metagenomi Therapeutics, Inc. (MGX) is a precision genetic medicines company developing curative therapeutics using a proprietary metagenomics-derived genome editing toolbox. This Form 10-Q covers the quarterly period ended June 30, 2024. The company completed its Initial Public Offering (IPO) in February 2024, raising approximately $80.7 million in net proceeds. As of June 30, 2024, the company had 37,459,853 shares of common stock outstanding.

Key Financial Metrics

Note: The company does not report product sales revenue; all revenue is derived from collaboration agreements.

Material Changes vs. Prior Period

• Revenue Increase: Collaboration revenue increased by $8.7 million (77%) for the three months ended June 30, 2024, compared to the same period in 2023. This was primarily driven by the recognition of $15.9 million in remaining deferred revenue from the Moderna agreement following its termination in April 2024.
• Expense Growth: Total operating expenses increased by $7.6 million for the quarter and $21.2 million for the six-month period compared to the prior year. R&D expenses rose due to increased headcount, laboratory materials, and stock-based compensation. G&A expenses increased due to public company costs and personnel expansion.
• Other Income: Total other income decreased by $2.9 million for the quarter, largely due to the absence of a $2.9 million gain from the change in fair value of long-term investments in Affini-T that was recorded in the prior year.
• Liquidity: Cash and cash equivalents decreased from $140.6 million at year-end 2023 to $61.2 million at June 30, 2024, while available-for-sale marketable securities increased from $130.6 million to $238.7 million. Total liquid assets remain robust at $299.9 million.

Guidance, Outlook, and Risks

• Moderna Termination: The company mutually terminated its Strategic Collaboration and License Agreement with Moderna on April 26, 2024. Metagenomi regained full development and commercialization rights to its base editing and RNA-mediated integration systems (RIGS) and the Primary Hyperoxaluria Type 1 (PH1) program. No future payments are expected from Moderna.
• Pipeline Updates:
  • Hemophilia A: Nominated lead development candidate MGX-001 in August 2024. Plans to file an IND in 2026.
  • Ionis Collaboration: All four Wave 1 targets (focusing on cardiometabolic diseases) advanced to lead optimization. The company expects to demonstrate in vivo proof-of-concept in 2024 and nominate one to two development candidates in 2025.
  • ALS Program: The company decided to deprioritize its Amyotrophic Lateral Sclerosis (ALS) program based on recent peer data regarding the lack of efficacy of the Ataxin-2 target.
• Liquidity Outlook: Management believes existing cash and marketable securities ($299.9 million) are sufficient to fund operations for at least the next 12 months and potentially into 2027 based on current plans.
• Risks: Key risks include the need for substantial additional funding, the novel nature of genome editing technology, regulatory uncertainty, and the high failure rate of clinical development. The company is an emerging growth company and has incurred significant losses since inception.

Investor Verification Checklist

• Revenue Sustainability: Verify the impact of the Moderna termination on future revenue streams, as the $15.9 million recognized in Q2 2024 was a one-time acceleration of deferred revenue.
• Burn Rate: Monitor the rate of cash consumption against the $299.9 million liquidity position to assess the runway for clinical trials and R&D.
• Ionis Milestones: Track progress on the four Wave 1 targets with Ionis Pharmaceuticals, as these represent the primary near-term revenue and development catalysts.
• Stock-Based Compensation: Review the $9.6 million in stock-based compensation expense for the six months ended June 30, 2024, and its impact on future dilution and expense recognition.
• Regulatory Pathway: Confirm the timeline for the Hemophilia A IND filing (targeted for 2026) and the status of the PH1 program following the regain of rights from Moderna.